NMBI, OSR, Emeramide or Irminex.
All are the same product.
If you have not heard of Emeramed's product, which is NMBI in America, it is a very successful mercury chelator that is anticipating FDA approval soon. It has been on the market as a supplement and it has a proven track record of removing mercury without the side effects of other methods.
Emeramed Background Information as of May 2018
Emeramed Ltd. is an Irish biotech company with subsidiaries in the USA and Sweden. They have produced a metals chelator and antioxidant currently known as NMBI. This product was formally distributed as a dietary supplement from 2008-2010 as OSR. It has also been known as Irminix and Emeramide.
NMBI is a metals chelator that should revolutionize the process of detoxing metals from the body. The product will bind and remove toxic metals such as mercury, lead, cadmium, arsenic, free iron, copper and zinc. It is also useful treating oxidative stress.
Unique Among Metals Chelator
NMBI is highly lipophilic, or fat soluble. To the consumer, that means that it has the ability to pass thru cell membranes and will also cross the blood-brain barrier to clear the brain of metals. This is a very important part of the detoxification process and of vital importance in finding wellness.
NMBI is not known to have any adverse side effects. Those who detox with more common methods know the vast number of side effects that can be painful, dangerous and harmful to the body. NMBI has none of these and in addition it does not deplete the body of elements that are essential to the body. It creates no damage to organs as it renders the metal inert and allows it to pass through the colon.
Currently the drug is only offered for compassionate use by most governing authorities. If you are interested in a copy of the forms to apply for early access, please see the link below.
The company is mandated to offer only a 14 day treatment of 300mg per day. The treatment length was designed to mimic the testing protocol used in Phase 1 and 2 of clinical trials. The amount needed will ultimately vary for patients, depending on the amount of exposure and the amount of stored metals in the body. There is no guarantee that doses allowed will be refilled. From past experience, the results show that even 14 days of use provides positive results in patients.
Early Access Program Information
Early access requires application to the company. If the application is accepted, your physician or dentist will be provided the documents necessary for application to the regulatory authority of your country.
There is no approval necessary for New Zealand. Austria and Germany are fairly liberal, with the USA being most difficult approval to obtain.
Step One of the process is to complete and return the application form to Emeramed. A copy of the application form to Emeramed can be obtained at the link below.